This article is more than 5 years old. Information may no longer be current.
NSAID reduces inflammation after cataract surgery
Click Here to Manage Email Alerts
SEATTLE — Once-daily 0.07% bromfenac ophthalmic solution safely reduces ocular inflammation after cataract surgery, according to a poster here.
“Compared to placebo, low-concentration, modified bromfenac ophthalmic solution dosed once daily effectively and safely reduced ocular inflammation associated with cataract surgery,” James A. Gow and colleagues said in a poster presented at the Association for Research in Vision and Ophthalmology annual meeting.
In a randomized, double-masked, placebo-controlled study of 440 subjects who underwent unilateral cataract surgery and posterior chamber IOL implantation, 6.6% of patients in the bromfenac group reported an adverse event in either the study eye or both eyes, compared 21.1% of patients in the placebo group.
Patients received one dose of Prolensa (bromfenac ophthalmic solution 0.07%, Bausch + Lomb) on the day before surgery and then daily for 14 days after surgery. Assessments were made on days 1, 3, 8 and 15 for incidence and frequency of ocular and systemic adverse events. Evaluations included visual acuity, slit lamp, IOP and dilated funduscopic examinations.
Disclosure: Gow is an employee at Bausch + Lomb.